Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada K, Aguirre AJ, et al
Wang J, Liu Y-T, Xiao L, Zhu L, Wang Q, Yan T
Increased body weight and body mass index (BMI) are associated with a greater incidence of non-alcoholic fatty liver disease (NAFLD) and its advanced forms, such as steatohepatitis, that can cause liver failure
The 7.5mg and 12.5mg intermediate doses were included in clinical protocols as transitional steps to improve tolerability but were not separate study arms in SURMOUNT-1
Strengths and limitations The review focused on the quantitative assessment of skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist by meta-analysis
Richardson agrees